Advanced Gastric and Gastroesophageal Cancer in Asia
Advanced Gastric and Gastroesophageal Cancer in Asia
Medical oncologists discuss the gastric and gastroesophageal cancer treatment landscape and disease prevalence in Asia
Medical oncologists discuss the gastric and gastroesophageal cancer treatment landscape and disease prevalence in Asia
Asst. Prof. Cheng Ean Chee, Dr Hisato Kawakami
Watch the video to learn about:
- The current treatment options for 2nd line and 3rd line gastric and gastroesophageal cancers
- Treatment selection strategies
- The latest research and clinical trials in 2nd line and 3rd line treatments
The video is divided into chapters for your convenience.
Build upon your learning further and download the accompanying slide set for your reference.
Asst. Prof. Cheng Ean Chee
Medical Oncologist
National University Cancer Institute
Singapore
Dr Cheng Ean Chee is an Assistant Professor of Medicine at Yong Loo Lin School of Medicine, National University of Singapore, Singapore. She completed medical school at University College London, United Kingdom and Internal Medicine Residency and Hematology-Oncology Fellowship at Mayo Clinic, Rochester, Minnesota, USA. Dr Chee is a clinician-investigator and medical oncologist in gastrointestinal and hepatobiliary cancers at the National University Cancer Institute, Singapore. She is also involved in phase I drug development and is the principal investigator of several phase I and gastrointestinal cancer trials at her institution. As the Program Director for the NUHS Medical Oncology Senior Residency (Fellowship) Program, she is actively involved in the education of the Medical Oncology trainees and she also chairs the Colorectal Cancer Committee of the Singapore Cancer Society. She is an active member of ASCO and the Asian Colorectal Cancer Oncology Group.
Asst. Prof. Cheng Ean Chee has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca (Advisory Board)
Dr Hisato Kawakami
Medical Oncologist
Kindai University
Japan
Dr Hisato Kawakami is an assistant professor in charge of clinical trials/research for gastrointestinal malignancies at the Department of Medical Oncology, Kindai University Faculty of Medicine in Osaka, Japan, where he has been employed since 2010. His professional specialty is medical oncology and gastroenterology, and his main research interests include molecular-targeted therapy and immunotherapy for gastrointestinal cancer.
Dr Kawakami graduated from Kumamoto University, earned his medical degree from Japanese Ministry of Health, Labor and Welfare, and his doctorate of philosophy from Kindai University. He currently utilises his expertise in scientific rationale-based translation of novel drugs, including molecular targeted therapy and immuno-oncology therapy, to develop and improve treatment strategies.
Dr Hisato Kawakami has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Consulting fees from Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Daiichi-Sankyo Co. Ltd., and Taiho Pharmaceutical Co. Ltd; honoraria from Bristol-Myers Squibb Co. Ltd., Bayer Yakuhin Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Merck Biopharma Co., Ltd., Takeda Pharmaceutical Co. Ltd., Yakult Pharmaceutical Industry, Teijin Pharma Ltd., and Taiho Pharmaceutical Co. Ltd.; lecture fees from Glaxo Smith Kline K.K., and Otsuka Pharmaceutical Co., Ltd.; and research funding from Chugai Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd, Kobayashi Pharmaceutical. Co., Ltd., and Eisai Co. Ltd.
Advanced gastric and gastroesophageal cancer in Asia
Video |
12 min
|
Jun 2023
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
Clinical Takeaways
-
Overall survival in patients with advanced gastric and GE cancers has improved with more effective systemic therapy
-
Current therapies in the second line and beyond setting may not be reflective of the changing landscape of first-line therapy in advanced disease, but trials are ongoing
-
Factors to consider when evaluating a patient for the second line and beyond therapy include prior lines of therapy and residual toxicities, performance status and competing comorbidities
-
PTX+RAM is the standard of care for second-line treatment, but there are multiple candidates for third-line treatment, which is not clearly defined
-
For HER2-positive gastric cancer, T-DXd was shown to be effective after trastsuzumab failure. Currently, the development of second-line therapy after trastsuzumab failure is the focus of attention
This educational programme is supported by an Independent Medical Education Grant from Bayer
GI CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer.